{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:45:15Z","timestamp":1791870315114,"version":"4.3.4"},"reference-count":110,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Monoclonal antibody therapy using CD38 as a target remains central to managing human multiple myeloma (MM). CD38 was selected early on as a target for mAb-mediated therapy for MM, driven by findings from an early Cluster of Differentiation (CD) Workshop. The first CD38-targeting antibody to be approved yielded strong trial results, significantly improving survival rates and earning widespread patient acceptance. However, resistance to the therapy later emerged, complicating treatment management. Despite CD38\u2019s still central role in MM therapy, too little attention has been paid to its broader roles\u2013not only as a myeloma marker but also as an enzyme and adhesion molecule in physiology. This review, a collaborative effort between basic scientists and clinical experts, explores some of the lesser-known mechanisms of antibody action and interactions with CD38 at key stages of treatment. The review also highlights the relevance of the MM environment, focusing on the importance of the bone marrow (BM) niche. The goal is to identify new agents whose unique properties may enhance tumor eradication. By gaining a deeper understanding of interactions between therapeutic antibodies, myeloma cells, and the tumor microenvironment (TME), it is hoped that previously unrecognized vulnerabilities within the disease may be revealed, paving the way to more effective treatment strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1519300","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T02:26:11Z","timestamp":1739327171000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects"],"prefix":"10.3389","volume":"16","author":[{"given":"Alberto L.","family":"Horenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo C.","family":"Faini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Ortolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Storti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Malavasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1269896","article-title":"Targeting NAD+ metabolism: dual roles in cancer treatment","volume":"14","author":"Yong","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2119\/2006\u201300086.Lee","article-title":"Structure and enzymatic functions of human CD38","volume":"12","author":"Lee","year":"2006","journal-title":"Mol Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2021.102514","article-title":"The calcium signaling enzyme CD38 - a paradigm for membrane topology defining distinct protein functions","volume":"101","author":"Lee","year":"2021","journal-title":"Cell Calcium"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/8.11.1643","article-title":"Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids","volume":"8","author":"Funaro","year":"1996","journal-title":"Int Immunol"},{"key":"B7","article-title":"Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha","volume":"54","author":"Drach","year":"1994","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005220","article-title":"Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed\/refractory multiple myeloma","volume":"5","author":"Frerichs","year":"2021","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-770776","article-title":"Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab","volume":"129","author":"Garc\u00eda-Guerrero","year":"2017","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1935-1","article-title":"Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors","volume":"66","author":"Wang","year":"2017","journal-title":"Vivo vitro Cancer Immunol Immunother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004332","article-title":"The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications","volume":"136","author":"Ogiya","year":"2020","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1077","article-title":"Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma","volume":"80","author":"Hu","year":"2020","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos","volume":"132","author":"Fedele","year":"2018","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101600","article-title":"Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse","volume":"111","author":"Mu\u00f1oz","year":"2008","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-4094","article-title":"MHC class II\/CD38\/CD9: a lipid-raft-dependent signaling complex in human monocytes","volume":"106","author":"Zilber","year":"2005","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2913","article-title":"CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells","volume":"107","author":"Frasca","year":"2006","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.7.2490","article-title":"Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells","volume":"99","author":"Deaglio","year":"2002","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350901","article-title":"Correct stimulation of CD28H arms NK cells against tumor cells","volume":"54","author":"Leau","year":"2024","journal-title":"Eur J Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1399-0039.1981.tb00663.x","article-title":"Modulation of expression of HLA components at the cell surface induced by anti-beta 2m reagents","volume":"17","author":"Ceppellini","year":"1981","journal-title":"Tissue Antigens"},{"key":"B21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/bjh.17329","article-title":"Molecular dynamics of targeting CD38 in multiple myeloma","volume":"193","author":"Malavasi","year":"2021","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","article-title":"Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting","volume":"35","author":"Viola","year":"2021","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through fc-dependent, independent, and direct pathways to kill multiple myeloma cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jim.2014.03.021","article-title":"Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies \u2014 Impact of effector cells","volume":"407","author":"Chung","year":"2014","journal-title":"J Immunol Methods"},{"key":"B26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/ejh.14270","article-title":"An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma","volume":"113","author":"Kapoor","year":"2024","journal-title":"Eur J Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2388306","article-title":"FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population","volume":"13","author":"Constantinides","year":"2024","journal-title":"OncoImmunology"},{"key":"B28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-1-0716-1450-1_18","article-title":"Methods for Functional Characterization of FcRn Interactions with Therapeutic Antibodies and Fc-Fusion Proteins","volume-title":"Therapeutic Antibodies. Methods in Molecular Biology","author":"Chung","year":"2022"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12561","article-title":"Drug-disease interaction and time-dependent population pharmacokinetics of isatuximab in relapsed\/refractory multiple myeloma patients","volume":"9","author":"Fau","year":"2020","journal-title":"CPT Pharmacom Syst Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12060817","article-title":"Roles of fcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of efgartigimod as an fcRn blocker","volume":"12","author":"Zhou","year":"2023","journal-title":"Pathogens"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2018.06.008","article-title":"A phylogenetic view of the leukocyte ectonucleotidases","volume":"205","author":"Ferrero","year":"2019","journal-title":"Immunol Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cells4030520","article-title":"NAD+-metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model","volume":"4","author":"Horenstein","year":"2015","journal-title":"Cells"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.2064.2064","article-title":"Ectoenzymes and their products as communicators in the human myeloma niche","volume":"124","author":"Horenstein","year":"2014","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.05.042","article-title":"Regulation of intracellular levels of NAD: a novel role for CD38","volume":"345","author":"Aksoy","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.05.100","article-title":"Decreased cADPR and increased NAD+ in the Cd38\u2013\/\u2013 mouse","volume":"346","author":"Young","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/1753425910361989","article-title":"Review: NAD + : A modulator of immune functions","volume":"17","author":"Grahnert","year":"2011","journal-title":"Innate Immun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-065x.1998.tb01568.x","article-title":"Ecto-phosphodiesterase\/pyrophosphatase of lymphocytes and non-lymphoid cells: structure and function of the PC-1 family","volume":"161","author":"Goding","year":"1998","journal-title":"Immunol Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26246","article-title":"A CD38\/CD203a\/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes","volume":"2","author":"Horenstein","year":"2013","journal-title":"OncoImmunology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2119\/molmed.2016.00198","article-title":"Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma","volume":"22","author":"Horenstein","year":"2016","journal-title":"Mol Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01187","article-title":"The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"22085","DOI":"10.1038\/s41598-023-49450-1","article-title":"Heavy-chain antibody targeting of CD38 NAD+ hydrolase ectoenzyme to prevent fibrosis in multiple organs","volume":"13","author":"Shi","year":"2023","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12020494","article-title":"CD38-induced metabolic dysfunction primes multiple myeloma cells for NAD+-lowering agents","volume":"12","author":"Becherini","year":"2023","journal-title":"Antioxid (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08824-3","article-title":"New insights on the role of TRP channels in calcium signalling and immunomodulation: review of pathways and implications for clinical practice","volume":"60","author":"Froghi","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1458809","article-title":"Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD","volume":"7","author":"Morandi","year":"2018","journal-title":"Oncoimmunology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmet.2017.10.006","article-title":"CD38-NAD+Axis regulates immunotherapeutic anti-tumor T cell response","volume":"27","author":"Chatterjee","year":"2018","journal-title":"Cell Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000987","article-title":"Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1\/PD-L1 immunotherapy in hepatocellular carcinoma","volume":"8","author":"Ng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04917-5","article-title":"Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes","volume":"101","author":"Leleu","year":"2022","journal-title":"Ann Hematol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6619","article-title":"Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma","volume":"12","author":"Bisht","year":"2023","journal-title":"Cancer Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbrc.2020.12.048","article-title":"Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma","volume":"536","author":"Lee","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and ab79","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121522","article-title":"Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab","volume":"8","author":"Martin","year":"2019","journal-title":"Cells"},{"key":"B55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.imlet.2018.04.005","article-title":"Immunomodulatory effects of CD38-targeting antibodies","volume":"199","author":"van de Donk","year":"2018","journal-title":"Immunol Lett"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00046.2020","article-title":"CD38 in the age of COVID-19: a medical perspective","volume":"101","author":"Horenstein","year":"2021","journal-title":"Physiol Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010076","article-title":"Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD+ Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells","volume":"13","author":"Baum","year":"2020","journal-title":"Cancers"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204844","article-title":"The circular life of human CD38: from basic science to clinics and back","volume":"25","author":"Horenstein","year":"2020","journal-title":"Molecules"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B63","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in hematological Malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a novel immunotherapy for multiple myeloma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100070","article-title":"CD47\u2013SIRP\u03b1-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immuno-Oncol Technol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16548","article-title":"CD14 + CD16 + monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy","volume":"190","author":"Storti","year":"2020","journal-title":"Br J Haematol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \u201cdon\u2019t eat me\u201d signal of CD47-SIRP\u03b1 in hematological Malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1398508","article-title":"Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic Malignancies expressing CD38","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1038\/s41467-024-46310-y","article-title":"Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma","volume":"15","author":"Grandcl\u00e9ment","year":"2024","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1410457","article-title":"Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13394","article-title":"Enhancing Fc -mediated effector functions of monoclonal antibodies: The example of HexaBodies","volume":"328","author":"Van Der Horst","year":"2024","journal-title":"Immunol Rev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104663","article-title":"Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity","volume":"93","author":"Hiemstra","year":"2023","journal-title":"EBioMedicine"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019451","article-title":"Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed\/refractory multiple myeloma","volume":"142","author":"Pouleau","year":"2023","journal-title":"Blood J"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-012542","article-title":"CD28-mediated regulation of multiple myeloma cell proliferation and survival","volume":"109","author":"Bahlis","year":"2007","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/cells13100879","article-title":"Pre-clinical assessment of SAR442257, a CD38\/CD3xCD28 trispecific T cell engager in treatment of relapsed\/refractory multiple myeloma","volume":"13","author":"Grab","year":"2024","journal-title":"Cells"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0434","article-title":"Ex vivo efficacy of SAR442257 anti-CD38 trispecific T-cell engager in multiple myeloma relapsed after daratumumab and BCMA-targeted therapies","volume":"4","author":"Keller","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013212","article-title":"Targeting CD38 with isatuximab and a novel CD38\/CD3\u00d7CD28 trispecific T-cell engager in older patients with acute myeloid leukemia","volume":"8","author":"Mart\u00edn-S\u00e1nchez","year":"2024","journal-title":"Blood Adv"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00821-1","article-title":"ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells","volume":"5","author":"Carretero-Iglesia","year":"2024","journal-title":"Nat Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2095949","article-title":"TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity","volume":"14","author":"Ugamraj","year":"2022","journal-title":"MAbs"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184533","article-title":"A fully human igE specific for CD38 as a potential therapy for multiple myeloma","volume":"15","author":"Candelaria","year":"2023","journal-title":"Cancers"},{"key":"B82","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13045-022-01395-0","article-title":"FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma","volume":"15","author":"Zhang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B83","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metast Rev"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.08.011","article-title":"Classifying cancer-associated fibroblasts\u2014The good, the bad, and the target","volume":"42","author":"Cords","year":"2024","journal-title":"Cancer Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp Mol Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41467-024-47068-z","article-title":"Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer","volume":"15","author":"Croizer","year":"2024","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1193978","article-title":"Cancer-associated fibroblasts in hematologic Malignancies: elucidating roles and spotlighting therapeutic targets","volume":"13","author":"Ding","year":"2023","journal-title":"Front Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"9671","DOI":"10.1038\/s41598-023-36092-6","article-title":"Cancer-associated fibroblast-derived exosome microRNA-21 promotes angiogenesis in multiple myeloma","volume":"13","author":"Miaomiao","year":"2023","journal-title":"Sci Rep"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012811","article-title":"Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma","volume":"139","author":"Sakemura","year":"2022","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0691-4","article-title":"Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial","volume":"12","author":"Saltarella","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9012152","article-title":"Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a","volume":"2017","author":"Cheng","year":"2017","journal-title":"Stem Cells Int"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18748","article-title":"Turning the spotlight on bone marrow adipocytes in haematological Malignancy and non-malignant conditions","volume":"201","author":"Austin","year":"2023","journal-title":"Br J Haematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100483","article-title":"High fat stems tumor immune surveillance","volume":"2","author":"Caruso","year":"2021","journal-title":"Cell Rep Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41586-020-2856-x","article-title":"snRNA-seq reveals a subpopulation of adipocytes that regulates thermogenesis","volume":"587","author":"Sun","year":"2020","journal-title":"Nature"},{"key":"B95","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cmet.2020.12.011","article-title":"Acetyl-coA synthetase 2: A critical linkage in obesity-induced tumorigenesis in myeloma","volume":"33","author":"Li","year":"2021","journal-title":"Cell Metab"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/21623945.2024.2313297","article-title":"Function of NAD metabolism in white adipose tissue: lessons from mouse models","volume":"13","author":"Kwon","year":"2024","journal-title":"Adipocyte"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100609","article-title":"Adipocytes and metabolism: Contributions to multiple myeloma","volume":"46","author":"Fairfield","year":"2024","journal-title":"J Bone Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/imr.13344","article-title":"Immunity in adipose tissues: Cutting through the fat","volume":"324","author":"Randall","year":"2024","journal-title":"Immunol Rev"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174347","article-title":"Unlocking drug resistance in multiple myeloma: adipocytes as modulators of treatment response","volume":"15","author":"Ochiai","year":"2023","journal-title":"Cancers"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013832","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"139","author":"Panaroni","year":"2022","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010822","article-title":"It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"7","author":"Choa","year":"2023","journal-title":"Blood Adv"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28548","article-title":"Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma","volume":"15","author":"El-Masri","year":"2024","journal-title":"Oncotarget"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1118691","article-title":"Obesity and myeloma: Clinical and mechanistic contributions to disease progression","volume":"14","author":"Marques-Mourlet","year":"2023","journal-title":"Front Endocrinol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.295","article-title":"Diet-induced obesity promotes a myeloma-like condition in vivo","volume":"29","author":"Lwin","year":"2015","journal-title":"Leukemia"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109814","article-title":"CD38 restrains the activity of extracellular cGAMP in a model of multiple myeloma","volume":"27","author":"Cuollo","year":"2024","journal-title":"iScience"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-809293","article-title":"The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents","volume":"131","author":"Gavriatopoulou","year":"2018","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107068","article-title":"Targeting CD38\/ADP-ribosyl cyclase as a novel therapeutic strategy for identification of three potent agonists for leukopenia treatment","volume":"200","author":"Liu","year":"2024","journal-title":"Pharmacol Res"},{"key":"B108","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev-immunol-051116-052433","article-title":"Signaling by antibodies: recent progress","volume":"35","author":"Bournazos","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0260","article-title":"Mechanism of action of a new anti-CD38 antibody: enhancing myeloma immunotherapy","volume":"25","author":"Malavasi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2909","article-title":"Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond","volume":"11","author":"Hogarth","year":"2012","journal-title":"Nat Rev Drug Discovery"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1519300\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T02:26:15Z","timestamp":1739327175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1519300\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":110,"alternative-id":["10.3389\/fimmu.2025.1519300"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1519300","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"article-number":"1519300"}}